LitAlert ~~ GeneLit.com

    • Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
    • Valero MG, Moo TA, Muhsen S, Zabor EC, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini V.
    • Br J Surg. 2020 May 20. doi: 10.1002/bjs.11616. Epub ahead of print.
    • Germline Mutation in MUS81 Resulting in Impaired Protein Stability is Associated with Familial Breast and Thyroid Cancer.
    • Pinheiro M, Sulla Lupinacci FC, Santiago KM, Drigo SA, Marchi FA, Fonseca-Alves CE, da Silva Andrade SC, Aagaard MM, Ramos Basso T, Bisarro dos Reis M, Rios Villacis RA, Roffé M, Maroso Hajj GN, Jurisica I, Kowalski LP, Achatz MI, Rogatto SR.
    • Cancers (Basel). 2020 May 20;12(5):E1289. doi: 10.3390/cancers12051289.
    • FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer
    • [No author given]
    • GenomeWeb. 2020 May 20.
    • Comparison of mutation profile between primary phyllodes tumors of the breast and their paired local recurrences.
    • Mitus J, Adamczyk A, Majchrzyk K, Kowalik A, Rys J, Niemiec J.
    • Pol J Pathol. 2020 May 20;71(1):7-12. doi: 10.5114/pjp.2020.94899.
    • Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome.
    • Santonocito C, Rizza R, Paris I, De Marchis L, Paolillo C, Tiberi G, Scambia G, Capoluongo E.
    • Cancers (Basel). 2020 May 19;12(5):E1286. doi: 10.3390/cancers12051286.
    • First PARP Inhibitor Approved for Metastatic Prostate Cancer.
    • Nelson R.
    • Medscape. 2020 May 19.